A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms telos
  • Sponsors AstraZeneca AB; Pearl Therapeutics
  • Most Recent Events

    • 24 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 12 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top